Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 108.00
-2.00 (-1.82%)
Aug 6, 2026, 3:30 PM JST
Delta-Fly Pharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
1.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | 300.00M | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.17B |
| Kohjin Bio | 4.94B |
| PhoenixBio | 1.57B |
| Human Metabolome Technologies | 1.30B |
| D. Western Therapeutics Institute | 305.97M |
| Cyfuse Biomedical K.K. | 234.00M |
| Kringle Pharma | 73.00M |
| FunPep Company | 3.00M |